Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epidemiology of human papillomavirus-related oropharyngeal cancer in a classically low-burden region of southern Europe

  • Mena, Marisa|||0000-0003-2163-892X
  • Frias-Gomez, Jon|||0000-0002-0366-676X
  • Taberna, Miren|||0000-0002-2446-186X
  • Quirós, Beatriz|||0000-0002-6187-3732
  • Marquez, Sandra
  • Clavero, Omar|||0000-0001-9721-6382
  • Baena, Antoni.|||0000-0001-9221-8784
  • Lloveras, Belen|||0000-0001-8659-5241
  • Alejo, María
  • León i Vintró, Xavier|||0000-0001-6286-630X
  • García, Jacinto Montero
  • Mesia, Ricard|||0000-0002-3785-3563
  • Bermejo, Josep Oriol|||0000-0002-8581-9415
  • Bonfill Abella, Teresa|||0000-0003-2775-0293
  • Aguilà, Antón
  • Guix, Marta|||0000-0002-2143-0697
  • Hijano, Rafael|||0000-0001-6787-5440
  • Pavón, Miguel Ángel|||0000-0003-3677-5329
  • Torres, Montserrat A.
  • Tous, Sara|||0000-0002-5423-7092
  • Clèries, Ramon|||0000-0002-3637-4747
  • Alemany, Laia|||0000-0003-0945-6015
The incidence of human papillomavirus (HPV)-related oropharyngeal cancer is increasing in some regions. Nevertheless, the epidemiology of this disease has not been extensively investigated in southern Europe. We conducted a retrospective cohort study of patients diagnosed with primary oropharyngeal cancer from 1991 to 2016. Cancer tissues underwent histopathological evaluation, DNA quality control, HPV-DNA detection and p16 immunohistochemistry. Data were collected from medical records. Factors associated with HPV positivity and time trends were evaluated with multivariable Bayesian models. The adjusted prevalence of HPV-related cases in 864 patients with a valid HPV-DNA result was 9.7%, with HPV-DNA/p16 double positivity being considered. HPV-related oropharyngeal cancer was likely to occur in non-smokers and non-drinkers, to be located in the tonsil or diagnosed at advanced stages. Time-trend analysis showed an increasing risk of HPV-related oropharyngeal cancer in the most recent periods (5-year period increase of 30%). This increase was highest and with a clear increasing trend only in the most recent years (2012-2016). The prevalence of HPV-related oropharyngeal cancer started to sharply increase in the most recent years in our setting, as occurred two decades ago in areas where most oropharyngeal cancer cases are currently HPV-related. Our results provide a comprehensive assessment of the epidemiological landscape of HPV-related oropharyngeal cancer in a region of southern Europe.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HPV-relatedness definitions for classifying HPV-related oropharyngeal cancer patient do impact on TNM classification and patients' survival

  • Taberna, Miren|||0000-0002-2446-186X
  • Mena, Marisa|||0000-0003-2163-892X
  • Tous, Sara|||0000-0002-5423-7092
  • Pavón, Miquel Angel
  • Oliva, Marc|||0000-0001-5352-8130
  • León i Vintró, Xavier|||0000-0001-6286-630X
  • Garcia Lorenzo, J|||0000-0002-6123-7808
  • Guix, Marta|||0000-0002-2143-0697
  • Hijano, Rafael|||0000-0001-6787-5440
  • Bonfill Abella, Teresa|||0000-0003-2775-0293
  • Aguilà, Antón
  • Alemany, Laia|||0000-0003-0945-6015
  • Mesia, Ricard|||0000-0002-3785-3563
Given the different nature and better outcomes of oropharyngeal carcinoma (OPC) associated with human papillomavirus (HPV) infection, a novel clinical stage classification for HPV-related OPC has been accepted for the 8 edition AJCC TNM (ICON-S model). However, it is still unclear the HPV-relatedness definition with best diagnostic accuracy and prognostic value. The aim of this study was to compare different staging system models proposed for HPV-related OPC patients: 7 edition AJCC TNM, RPA stage with non-anatomic factors (Princess Margaret), RPA with N categories for nasopharyngeal cancer (MD-Anderson) and AHR-new (ICON-S), according to different HPV-relatedness definitions: HPV-DNA detection plus an additional positive marker (p16 or HPV-mRNA), p16 positivity alone or the combination of HPV-DNA/p16 positivity as diagnostic tests. A total of 788 consecutive OPC cases diagnosed from 1991 to 2013 were considered eligible for the analysis. Of these samples, 66 (8.4%) were positive for HPV-DNA and (p16 or HPV-mRNA), 83 (10.5%) were p16 positive and 58 (7.4%) were double positive for HPV-DNA/p16. ICON-S model was the staging system, which performed better in our series when using at least two biomarkers to define HPV-causality. When the same analysis was performed considering only p16-positivity, RPA stage with non-anatomic factors (Princess Margaret) has the best classification based on AIC criteria. HPV-relatedness definition for classifying HPV-related OPC patient do impact on TNM classification and patients' survival. Further studies assessing HPV-relatedness definitions are warranted to better classify HPV-related OPC patients in the era of de-escalation clinical trials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

uPA/uPAR and SERPINE1 in head and neck cancer, Role in tumor resistance, metastasis, prognosis and therapy

  • Pavón, Miguel Angel
  • Arroyo Solera, Irene|||0000-0003-0425-1483
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • León i Vintró, Xavier|||0000-0001-6286-630X
  • Mangues, Ramon|||0000-0003-2661-9525
There is strong evidence supporting the role of the plasminogen activator system in head and neck squamous cell carcinoma (HNSCC), particularly of its uPA (urokinase plasminogen activator)/uPAR (urokinase plasminogen activator receptor) and SERPINE1 components. Overexpression of uPA/uPAR and SERPINE1 enhances tumor cell migration and invasion and plays a key role in metastasis development, conferring poor prognosis. The apparent paradox of uPA/uPAR and its inhibitor SERPINE1 producing similar effects is solved by the identification of SERPINE1 activated signaling pathways independent of uPA inhibition. Both uPA/uPAR and SERPINE1 are directly linked to the induction of epithelial-to-mesenchymal transition, the acquisition of stem cell properties and resistance to antitumor agents. The aim of this review is to provide insight on the deregulation of these proteins in all these processes. We also summarize their potential value as prognostic biomarkers or potential drug targets in HNSCC patients. Concomitant overexpression of uPA/uPAR and SERPINE1 is associated with a higher risk of metastasis and could be used to identify patients that would benefit from an adjuvant treatment. In the future, the specific inhibitors of uPA/uPAR and SERPINE1, which are still under development, could be used to design new therapeutic strategies in HNSCCs.